Journal of Renal Nutrition
Volume 18, Issue 4 , Pages 375-382, July 2008

Prevalence of Vitamin D [25(OH)D] Deficiency and Effects of Supplementation With Ergocalciferol (Vitamin D2) in Stage 5 Chronic Kidney Disease Patients

  • Debra Blair, MPH, RD, CSR

      Affiliations

    • Fresenius Medical Care, Western Massachusetts Kidney Center, Springfield, Massachusetts
    • Corresponding Author InformationAddress reprint requests to Debra Blair, MPH, RD, CSR, Fresenius Medical Care, Western Massachusetts Kidney Center, 2000 Main St., Springfield, MA 01103.
  • ,
  • Laura Byham-Gray, PhD, RD

      Affiliations

    • Department of Nutritional Sciences, School of Health Related Professions, University of Medicine and Dentistry of New Jersey, Stratford, New Jersey
  • ,
  • Emily Lewis, MS, RD

      Affiliations

    • Fresenius Medical Care, Chicopee Dialysis, Chicopee, Massachusetts
  • ,
  • Susan McCaffrey, MS, RD

      Affiliations

    • Fresenius Medical Care, Ludlow Dialysis, Ludlow, Massachusetts

This article has an online CPE activity available at www.kidney.org/professionals/CRN/ceuMain.cfm

Objective

This study investigated the prevalence of vitamin D deficiency, its association with nutrition-related parameters, and the effects of ergocalciferol supplementation in stage 5 chronic kidney disease (CKD). Measures of interest included serum albumin, glycosylated hemoglobin (HgA1c), hemoglobin, phosphorus, corrected calcium, parathyroid hormone (iPTH), equilibrated normalized protein catabolic rate (enPCR), and quality-of life-survey physical component score (SF-36 PCS).

Design and Setting

This retrospective study was conducted at five dialysis centers in western Massachusetts. Patient records were examined for a 6-month period in 2006, after initiation of a protocol to assess serum 25(OH)D and implement treatment with ergocalciferol if the level of serum 25(OH)D were <40 ng/mL.

Results

Over 90% (i.e., 92.4%) of patients had vitamin D levels of less than 40 ng/mL; 80% had vitamin D levels at 31 ng/mL or less. Ergocalciferol supplementation (50,000 IU/week × 24) was associated with significant improvements in serum 25(OH)D from baseline (18.4 ± 9.0 ng/mL; mean ± SD) to 6 months (42.0 ± 24.7 ng/mL) (P < .0005). The level of glycosylated hemoglobin decreased from 6.9% ± 1.9% at baseline to 6.4% ± 1.5% at 6 months (P < .0005), while hemoglobin improved from 12.1 ± 1.6 g/dL to 12.3 ± 1.4 g/dL (P < .0005). Corrected calcium decreased from 8.7 ± 0.8 mg/dL to 8.5 ± 0.9 mg/dL at 6 months (P = .002). Phosphorus and iPTH exhibited a downward trend, though not significantly. Albumin remained stable, while enPCR increased (0.91 ± 0.23 at baseline, vs. 0.98 ± 0.32 at 6 months) (P = .01). The SF-36 PCS scores did not differ significantly from baseline (35.4 ± 11.8) at 6 months (35.0 ± 11.1).

Conclusions

Vitamin D [25(OH)D] deficiency appears to be widely prevalent in stage 5 CKD. Repletion with ergocalciferol may assist in improving glycemic control in the management of diabetes. Additional research is needed to confirm these results and determine the optimal levels of serum 25(OH)D.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1051-2276(08)00301-4

doi:10.1053/j.jrn.2008.04.008

Refers to erratum:

Journal of Renal Nutrition
Volume 18, Issue 4 , Pages 375-382, July 2008